287114-37-8

Basic information

• Product Name: 3-Pyridinol,6-(1-piperazinyl)-(9CI)
• Synonyms: 3-Pyridinol,6-(1-piperazinyl)-(9CI);6-PIPERAZIN-1-YLPYRIDIN-3-OL
• CAS NO: 287114-37-8
• Molecular Formula: C₉H₁₃N₃O
• Molecular Weight: 179.22
• Product Categories: PIPERIDINE
• Mol File: 287114-37-8.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 449.8±40.0 °C(Predicted)
• Appearance: /
• Density: 1.199±0.06 g/cm3(Predicted)
• PKA: 11.32±0.29(Predicted)
• CAS DataBase Reference: 3-Pyridinol,6-(1-piperazinyl)-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinol,6-(1-piperazinyl)-(9CI)(287114-37-8)
• EPA Substance Registry System: 3-Pyridinol,6-(1-piperazinyl)-(9CI)(287114-37-8)

Safety Data

• Hazardous Substances Data: 287114-37-8(Hazardous Substances Data)

Upstream product

• 41288-96-4 6-chloropyridine-3-ol 
• 823197-35-9 1-[5-(benzyloxy)pyridin-2-yl]piperazine 
• 84611-43-8 5-(benzyloxy)-2-chloropyridine 
• 110-85-0 piperazine 
• 6737-42-4 1,3-bis-(diphenylphosphino)propane 
• 861965-90-4 benzyl 4-(5-methoxypyridin-2-yl)piperazine-1-carboxylate 

Relevant articles and documents

MALIC ENZYME INHIBITORS

The present invention relates to novel compounds useful as malic enzyme (ME) inhibitors, processes for their preparation and use of these compounds for the therapeutic treatment of disorders mediated by ME such as cancers (e.g. pancreatic ductal adenocarcinoma (PDAC)) in humans.

MEDICINAL COMPOSITION

The present invention is composed of a pharmaceutical composition for the therapy of nephritis which comprises an amide derivative represented by the following formula [1] or pharmaceutically acceptable salt thereof, as an active ingredient: ???wherein R1 and R2 may be the same or different and each is hydrogen, alkyl which may be substituted, acyl, aryl which may be substituted, or an aromatic heterocyclic group which may be substituted; R3, R4, R5 and R6 may be the same or different and each is hydrogen, halogen, hydroxy, amino which may be substituted, alkyl which may be substituted, alkoxy or nitro and the like; and R7 represents cyclic amino which may be substituted or azabicycloalkylamino which may be substituted. The pharmaceutical composition of the invention is useful for the therapy of nephritis.